The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases

Recruiting now · Not applicable

Conditions studied: Liver Metastases From Colorectal Cancer

In brief

FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM). Fibroblast activation protein inhibitors (FAPIs), which are the focus of this imaging modality, selectively target cancer-associated fibroblasts, a critical component of the tumor microenvironment. FAPI PET/CT could be useful in the detection of HGP (Histological Growth Pattern) and in the changes during neoadjuvant chemotherapy prior to surgery

Key facts

Study ID

NCT07109440

Run by

Jules Bordet Institute

People needed

50

Starts

2025-05-09

Expected to finish

2028-12-01

Last updated by the study team

2025-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age above 18 years.
• Liver metastasis on standard imaging for the initial assessment (MRI, FDG PET/CT)
• Naïve for treatment or after neoadjuvant chemotherapy
• Scheduled for liver metastasis resection
• ECOG Performance status ≤2.
• Signed written informed consent

You may not qualify if…

• Non-resectable liver metastases
• Pregnant and lactating women
• Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.

Where it is running

• Institut Jules Bordet — Brussels, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.